FDA Scrutiny on Sarepta - Search News

Order byBest matchMost fresh

News

Gene Therapy Stays on Market Despite FDA Request

· 3d · on MSN

Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys

U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a muscular dystrophy patient who received a different, experimental treatment died,

Continue reading

InvestorsHub on MSN · 15h

Sarepta Shares Drop as FDA Suspends Gene Therapy Trials for Muscular Dystrophy

Fierce Pharma · 15h

Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market

pharmaphorum20h

Sarepta resists as FDA seeks pause on Elevidys use

Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...

Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results